Reuters: Global Markets: Pfizer quarterly revenue falls far short of forecasts

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Pfizer quarterly revenue falls far short of forecasts Nov 1st 2012, 11:49 Tweet Share this Email Print Related News GM sees European operations breaking even by mid-decade Wed, Oct 31 2012 Electronic Arts third-quarter forecast disappoints as "Medal" lags Tue, Oct 30 2012 Applebee's owner's third-quarter profit tops Street estimate Tue, Oct 30 2012 Tax gains lift Merck profits, but sales disappoint Fri, Oct 26 2012 Amazon reports first quarterly net loss in years Thu, Oct 25 2012 Analysis & Opinion Apple results shrink iPad mini’s relevance Procter & Gamble earnings give CEO McDonald some relief Related Topics Investing Simplified » Health » Hot Stocks » Asian Markets » Money » People walk past the Pfizer World headquarters in New York, February 3, 2010. Credit: Reuters/Brendan McDermid Thu Nov 1, 2012 7:49am EDT (Reuters) - Pfizer Inc reported on Thursday quarterly revenue well below Wall Street expectations, on sharply weaker sales of specialty care drugs and a pullback of emerging market revenue. Results were also hurt by weaker than expected sales of Pfizer's Prevnar vaccine and Lipitor cholesterol fighter, which has been facing cheaper generics since late last year. The largest U.S. drugmaker earned $3.21 billion, or 43 cents per share, in the third quarter. That compared with $3.74 billion, or 48 cents per share, in the year-earlier period, when the company recorded a $1.3 billion gain on the sale of its Capsugel business. Excluding special items, Pfizer earned 53 cents per share. Analysts on average had expected 53 cents, according to Thomson Reuters I/B/E/S. Global sales fell 16 percent to $13.98 billion, well below Wall Street expectations of $14.64 billion. (Reporting by Ransdell Pierson; Editing by Lisa Von Ahn and Gerald E. McCormick) Related Quotes and News Company Price Related News Tweet this Link this Share this Digg this Email Reprints We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/ Comments (0) Be the first to comment on reuters.com. Add yours using the box above.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions